EVNIN LUKE sold $43K of HOWL (indirect holdings)
EVNIN LUKE sold 105,565 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.41 ($0.40–$0.44) across 3 trades over 2026-06-04 to 2026-06-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure can influence sentiment, but it does not provide new operational/financial information about Werewolf Therapeutics.
Market read
A planned insider sale is disclosed; any trading impact is likely limited unless the market interprets it as a broader confidence signal.
What to watch
Traders should check whether there were concurrent insider buys/sales by other insiders and whether the stock’s liquidity makes small insider sales more price-sensitive than usual.
Background
SEC Form 4 reports an insider’s equity transaction; here it is an open-market sale by a director using a Rule 10b5-1 plan.
Ticker impact
Werewolf Therapeutics director EVNIN LUKE sold 105,565 shares in open-market transactions under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect should be small and fade unless accompanied by other negative news.
Form 4 is primary-source, but the article describes a planned 10b5-1 sale with relatively small dollar value versus typical microcap liquidity; no new company fundamentals are disclosed.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect diversification/tax planning rather than bearish expectations.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure (HOWL).
- insiderEVNIN LUKE
Director who sold 105,565 shares via open-market transactions under a 10b5-1 plan.
